{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Iiw-qMJDA","lastupdate":"2023-06-30T00:00:00.000Z","update_date":"2023-06-30T00:00:00.000Z","lastModified":"Oct 2, 2025","active":1,"confidence_score":99,"confidence_score_reason":"markets","urlname":"trobix-bio","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$KMq93ndtEielJDWF6pXMadGCg2Ub15CA1K0GuamRkcZx43QMfnSgsa","name":"Trobix Bio","oneliner":"Phage-based Antimicrobial Resistance-sensitizing Solutions","registrar":"515823276","website":"https://www.trobix.bio/cgi-sys/suspendedpage.cgi","careerspage":"","founded_month":3,"founded_year":2019,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCeVk8zmbxKHckr9Cc5kebVg","facebook":"","linkedin":"https://www.linkedin.com/company/40967811","instagram":""},"social":["https://www.linkedin.com/company/40967811","https://www.youtube.com/channel/UCeVk8zmbxKHckr9Cc5kebVg"],"flattenedsociallinks":"https://www.linkedin.com/company/40967811|https://www.youtube.com/channel/UCeVk8zmbxKHckr9Cc5kebVg","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":6,"patent":0,"raised":8200000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Trobix.Bio","TrobixBio","Trobix-Bio","Trobix Innovation"],"about":"Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.\n\nTargeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.\n\nTrobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"257aaa69-f59e-40b7-898c-660a3a23933f","city":"Netanya","type":null,"address":"HaMelacha St 45, Netanya, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"hrMEZ443jJHs7tkPPUKyLFvjcudwnCki7fmZ7DFC3jAGaLXzlciGth","date":"Mar 30, 2023","link":"https://www.globenewswire.com/en/news-release/2023/03/30/2637334/0/en/Trobix-Bio-Raises-3-Million-from-Chartered-Group-to-Advance-Precision-Microbiome-Oncology-Therapeutics.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"precision microbiome oncology therapeutics","company":"Trobix Bio","layoffs":null,"summary":"Trobix Bio has successfully closed a $3 million equity investment by Chartered Group. The investment will be used to advance the development of Trobix Bios precision microbiome oncology therapeutics, which aim to address the gastrointestinal side effects of oncology treatments and other gastrointestinal diseases impacted by the microbiome. Trobix Bios CEO expressed gratitude for the investment and highlighted the significant unmet need for treatments that relieve side effects caused by cancer therapeutics. Chartered Groups Chairman praised Trobix Bios technology and team, stating that they believe the company will deliver products that make a huge impact on human wellbeing. Trobix Bios proprietary TBX™ platform technology utilizes computational, synthetic, and synthetic biology technologies to engineer phages as medicines that reprogram targeted microbiome bacteria. The companys lead therapeutic candidates, TBX201 and TBX301, aim to reduce severe diarrhea caused by irinotecan and colitis in patients receiving immune checkpoint inhibitors, respectively.","partners":null,"customers":null,"investors":"Chartered Group","confidence":9,"key_topics":["CRISPR","phage","synthetic biology","precision microbiome oncology therapeutics","equity investment"],"date_of_event":"March 30, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$3 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aGa5tyUh9eQIQHFv6bk19o1nJXMFOT4bAkT6f7zS9xFJnXst9poQjT","news_summary":"Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1ddcd2c0-a9a2-413b-8933-6f37364ee1f3","date":"Jul 29, 2020","link":"https://www.prnewswire.com/news-releases/trobix-bio-completed-series-a-funding-by-a-leading-japanesesingapore-fund-301101909.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"funding","company":"Trobix Innovation Ltd. (Trobix Bio)","layoffs":null,"summary":"Trobix Bio, a biotechnology company, has announced the closing of a US $3 million Series A funding from its lead investor, Chartered Opus. The funding will be used to advance the companys antimicrobial resistance platform technology and the pre-clinical development of its lead product, TBX101. Trobix Bio aims to develop phage-based products that sensitize bacterial pathogens to antibiotics and treat patients carrying gut antimicrobial resistant bacteria. The funding is seen as a positive growth opportunity for the company. Chartered Opus, a production platform for investment products, is the preferred investment vehicle for the Chartered Group High-Tech division.","partners":null,"customers":null,"investors":"Chartered Opus","confidence":9,"key_topics":["funding","antimicrobial resistance","pre-clinical development","phage-based nanomedicine","precision medicine technology"],"date_of_event":"July 29, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$3 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0dsj7yZ8bAt39oeqWn7D5WyfNMIR5j12wuJ2HGzizbFooE6zsl22k9","news_summary":"Trobix Bio completed Series A funding by a leading Japanese/Singapore fund","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"71ca1ae4-4bfc-427b-aec1-49040b62ccbb","date":"Jul 6, 2020","link":"https://ramot.org/news/2020/trobix-bio-selected-as-a-one-to-watch-in-this-years-spinoff-prize","source":"ramot.org","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZPnVhBLA8IH8j6xcbzVn26PTpCQstri92Rzzmb3CH53PE6KplxZ4wz","news_summary":"Ramot- Technology Transfer Company of Tel Aviv University","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"b3cc7fe1-c191-4b79-bd32-673e142f157b","date":"Mar 6, 2019","link":"https://globaluniversityventuring.com/trobix-bio-follows-the-funding-trail/","source":"globaluniversityventuring.com","visible":1,"analysis":{"tags":"spin-out","company":"Trobix Bio","layoffs":null,"summary":"Trobix Bio, an Israel-based developer of enhanced antibiotics spun out of Tel Aviv University research, has received undisclosed funding led by Chartered Opus.","partners":null,"customers":null,"investors":"Chartered Opus","confidence":8,"key_topics":["Trobix Bio","antibacterial resistance","funding","investors","spin-out"],"date_of_event":"March 6, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"eIaZK0RGKXWWZInWu0ZDhjJdu5IPxuP4FnIUlpj1N3urrl4Woapctk","news_summary":"Trobix Bio follows the funding trail - Global Venturing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":4,"techcommunityinvolvement":null,"mediagallery":[{"id":"73dbf93d-ba59-4c00-b2fe-4874a5482560","timestamp":"2020-07-30 08:11:37.000000","resources_type":2,"resources_title":"TROBIX BIO","resources_file_name":"h1MsWkhBAyM","alt":"TROBIX BIO logo","imageurl":"https://img.youtube.com/vi/h1MsWkhBAyM/0.jpg","url":"http://youtu.be/h1MsWkhBAyM"}],"tags":["therapeutics","infection","drug-discovery","antibiotics","pharmaceuticals","patent-pending","precision-medicine","nanotechnology","bioconvergence"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"technologysuccessstory":[{"date":"2019-03-01","name":"Using Bacteriophages to Reverse Antibiotic Resistance of Pathogens","tags":["pharmaceuticals","infection","biopharmaceutical","bacteria","biotechnology","antibiotics"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/ramot_tto_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda7","university_logo":"/image_cloud/ramot_institution_logo_f01045b8-6016-11e8-8e45-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["TBX 201","TBX101","TBX 301"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$3M","totalrounds":4,"fundingstage":"A","totalfunding":"$8.2M","publicinvestors":2,"lastpublicfunding":3000000,"totalpublicrounds":4,"totalpublicfunding":8200000},"team":[{"name":"Adi Elkeles","email":"aelkeles@gmail.com","phone":"0546402333","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Kjlir8JDA","bounced":false,"claimed":1,"founder":1,"urlname":"adi-elkeles","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgqOWeoQoM","position":"Co-founder & CEO","last_name":"Elkeles","claimtoken":"b937eb12a1e26897b46f07c8868caf8c85779b3d3911bdbe32e95d8d476f4006","first_name":"Adi","picturekey":"$i7EmDbW4OpH0IeWFeFCkHWe5AYsS4vVhAWpXUGR8mOEcPoHJdkBjoZ","claimeddate":"2019-11-17","linkedinurl":"https://www.linkedin.com/in/adielkeles/","unsubscribed":false,"is_activeuser":1,"additionalemail":"adi@trobixbio.com","claimedemaildate":"2019-11-17 14:12:34.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$i7EmDbW4OpH0IeWFeFCkHWe5AYsS4vVhAWpXUGR8mOEcPoHJdkBjoZ","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ziv  Lifshitz","email":"ziv@trobixbio.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LHltYcKDA","bounced":true,"claimed":0,"founder":0,"urlname":"ziv-lifshitz-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgsceElgsM","position":"Director of R&D","last_name":"Lifshitz","claimtoken":"EnY4t2qzFGlU7z1PleVrSljZJfl9Bvnhk1rD0BEGyfyWpnBzZoHH4l","first_name":"Ziv ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/zivlifshitz/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-30 13:23:25.000000","initials":"ZL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwN25h58KDA","fullname":"Vered Waxman"},"biverifydate":"2019-11-18T00:00:00.000Z","crunchbaseid":"trobix-innovations-trobix-bio","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2019-03-07T00:00:00.000Z","biverification":"Vered Waxman","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"S3GMG3gFoj4RGy8s9tjGmkx2PKmqIkOda39OkQUmIeRyu9tCQigifR","date":"Mar 2023","amount":"$3M","source":"https://www.globenewswire.com/en/news-release/2023/03/30/2637334/0/en/Trobix-Bio-Raises-3-Million-from-Chartered-Group-to-Advance-Precision-Microbiome-Oncology-Therapeutics.html","eventtype":"FundingRoundEvent","investment":[{"name":"The Chartered Group","type":"Investor","amount":null,"hidden":false,"country":"Singapore","fullurl":"/investor_page/the-chartered-group","logokey":"$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","tagline":null,"urlname":"/investor_page/the-chartered-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OOi_L4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"FAf3xf9oWKT9tnnFnh8fsSh5lkViK7lz3bOaJGGfwoL006TEZvODIo","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":3000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODJlKKQCgw","date":"Jul 2020","amount":"$3M","source":"https://www.prnewswire.com/news-releases/trobix-bio-completed-series-a-funding-by-a-leading-japanesesingapore-fund-301101909.html","eventtype":"FundingRoundEvent","investment":[{"name":"The Chartered Group","type":"Investor","amount":0,"hidden":false,"country":"Singapore","fullurl":"/investor_page/the-chartered-group","logokey":"$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","tagline":null,"urlname":"/investor_page/the-chartered-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OOi_L4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"96c0de9c-0fdd-4dba-b5fa-0a6bc2d06271","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","leadcaption":"Lead ","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCqsMXZCgw","date":"Sep 2019","amount":"Undisclosed","source":"","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"0c70bbe0-59fa-49a8-af75-49979bc38593","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtfqkCAw","date":"Mar 2019","amount":"$2.2M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Momentum Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/momentum-fund","logokey":"$jFduI2ECUBpjAhaecgyr0lBqplh9fo2MiUJrHF7fEJh8YQ8JkcrDKF","tagline":null,"urlname":"/investor_page/momentum-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PDanZgKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"31206db7-6fa9-4350-a2ed-9c5159117c8b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$jFduI2ECUBpjAhaecgyr0lBqplh9fo2MiUJrHF7fEJh8YQ8JkcrDKF","leadcaption":"","followupcaption":""},{"name":"The Chartered Group","type":"Investor","amount":0,"hidden":false,"country":"Singapore","fullurl":"/investor_page/the-chartered-group","logokey":"$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","tagline":null,"urlname":"/investor_page/the-chartered-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OOi_L4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5997b205-93d1-4a29-bfb2-bbb111100f5d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"3/2019","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Trobix Bio","logourl":"https://storage.googleapis.com/clean-finder-353810/$KMq93ndtEielJDWF6pXMadGCg2Ub15CA1K0GuamRkcZx43QMfnSgsa","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$KMq93ndtEielJDWF6pXMadGCg2Ub15CA1K0GuamRkcZx43QMfnSgsa","seoabout":"Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic b...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"S3GMG3gFoj4RGy8s9tjGmkx2PKmqIkOda39OkQUmIeRyu9tCQigifR","date":"Mar 2023","amount":"$3M","source":"https://www.globenewswire.com/en/news-release/2023/03/30/2637334/0/en/Trobix-Bio-Raises-3-Million-from-Chartered-Group-to-Advance-Precision-Microbiome-Oncology-Therapeutics.html","eventtype":"FundingRoundEvent","investment":[{"name":"The Chartered Group","type":"Investor","amount":null,"hidden":false,"country":"Singapore","fullurl":"/investor_page/the-chartered-group","logokey":"$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","tagline":null,"urlname":"/investor_page/the-chartered-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OOi_L4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"FAf3xf9oWKT9tnnFnh8fsSh5lkViK7lz3bOaJGGfwoL006TEZvODIo","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":3000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODJlKKQCgw","date":"Jul 2020","amount":"$3M","source":"https://www.prnewswire.com/news-releases/trobix-bio-completed-series-a-funding-by-a-leading-japanesesingapore-fund-301101909.html","eventtype":"FundingRoundEvent","investment":[{"name":"The Chartered Group","type":"Investor","amount":0,"hidden":false,"country":"Singapore","fullurl":"/investor_page/the-chartered-group","logokey":"$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","tagline":null,"urlname":"/investor_page/the-chartered-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OOi_L4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"96c0de9c-0fdd-4dba-b5fa-0a6bc2d06271","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","leadcaption":"Lead ","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtfqkCAw","date":"Mar 2019","amount":"$2.2M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Momentum Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/momentum-fund","logokey":"$jFduI2ECUBpjAhaecgyr0lBqplh9fo2MiUJrHF7fEJh8YQ8JkcrDKF","tagline":null,"urlname":"/investor_page/momentum-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PDanZgKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"31206db7-6fa9-4350-a2ed-9c5159117c8b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$jFduI2ECUBpjAhaecgyr0lBqplh9fo2MiUJrHF7fEJh8YQ8JkcrDKF","leadcaption":"","followupcaption":""},{"name":"The Chartered Group","type":"Investor","amount":0,"hidden":false,"country":"Singapore","fullurl":"/investor_page/the-chartered-group","logokey":"$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","tagline":null,"urlname":"/investor_page/the-chartered-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4OOi_L4KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5997b205-93d1-4a29-bfb2-bbb111100f5d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Bf6GMGiRYJKo0nGQ1Enh4TYYYIpJgAEwIfDN8GTsXPZtLjvUxTyTCX","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCqsMXZCgw","date":"Sep 2019","amount":"Undisclosed","source":"","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"0c70bbe0-59fa-49a8-af75-49979bc38593","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}